Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Authors: Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet 2021 cited by 394